Celularity Inc.
Press
Releases
April 16, 2021
GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination
NEW YORK, April 16, 2021 /PRNewswire/ — On April 14, 2021, GX Acquisition Corp. (“GX”) (NASDAQ: “GXGX”), provided information regarding a proposal to amend...
April 13, 2021
Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas
FLORHAM PARK, N.J., April 13, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution...
April 9, 2021
Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Presentations to showcase updates related to multiple Celularity programs in immuno-oncology and infectious disease FLORHAM PARK, N.J., April 09, 2021...
March 18, 2021
Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme
FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution...
FLORHAM PARK, N.J., March 09, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company focused on the development...